When would you consider switching to or adding on a PCSK9 inhibitor to lipid-lowering therapy following hospital discharge for acute coronary syndrome, in light of the results of the VICTORION-INCEPTION trial, provided LDL is still not at goal?

I don’t think the trial really changed my mind on this. I never really worried about not having ACS patients in the original phase 3 trials, so I had already been using inclisiran when I could in recent ACS patients.

I would never switch from a statin to a PCSK9i. Statins are cheap, effective, and w...

The VICTORION-INCEPTION trial looked at LDL-lowering with inclisiran following AMI. I don't know that it enhanced my knowledge or toolkit - as I would have assumed this to be the case - inclisiran offers further LDL-lowering (~40% reduction) compared with usual care. Practically, it is hard to get c...

My thinking is that the LDL Target should be at least 50, if not lower. I don't see setting an arbitrary goal of 70 being adequate. I think there's likely benefit to additional lowering, maybe not linear, but at least additive.

Yes, I think trying to impress this upon patients is difficult, but when...